Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRABTRAP phase III trial of trabectedin versus trabectedin plus tTF-NGR in metastatic or refractory soft tissue sarcoma
2024-516392-33-00Phase 3Authorised
- Sponsor
- Universität Münster
- Start
- Sep 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in soft tissue sarcoma (STS) comparing Trabectedin with Trabectedin + tTF-NGR (2 arms). Primary endpoint: Progression-free survival. Planned start Sep 2024; status: authorised.
02
Drugs
trabectedintTF-NGR
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on 2024-516392-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516392-33-00.